A systematic review of PCSK9 inhibitors alirocumab and evolocumab

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 6, 2016, Pages 641-653

  McDonagh, Marian ^a   Peterson, Kim ^a   Holzhammer, Brittany ^a   Fazio, Sergio ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EVOLOCUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ENZYME INHIBITOR; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROENTERITIS; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; INJECTION SITE REACTION; INTERNAL VALIDITY; ISCHEMIC HEART DISEASE; MEDICAL DECISION MAKING; MENTAL DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; HYPERCHOLESTEROLEMIA; METABOLISM; PROCEDURES;

ANIMALS; ANTIBODIES, MONOCLONAL; ENZYME INHIBITORS; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASE 9; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84977489326     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.22.6.641     Document Type: Article

References (46)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
2. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-90.
3. Evolocumab (Repatha)-a second PCSK9 inhibitor to lower LDLcholesterol. JAMA. 2015;314(21):2298-99.
4. Carroll J. UPDATED: Amgen gets a big win with FDA OK for PCSK9 cholesterol drug Repatha. FierceBiotech. August 27, 2015. Available at:http://www.fiercebiotech.com/story/amgen-gets-big-win-fda-ok-pcsk9-drugrepatha/2015-08-27. Accessed April 12, 2016.
5. Pollack A. New drug sharply lowers cholesterol, but it's costly. The New York Times. July 24, 2015. Available at: http://www.nytimes.com/2015/07/25/ business/us-approves-drug-that-can-sharply-lower-cholesterol-levels. html?ref=health. Accessed April 12, 2016.
6. Staton T. Payers fret about the next drug doomsday: pricey PCSK9 cholesterol meds. FiercePharmaMarketing. May 7, 2014. Available at: http://www. fiercepharmamarketing.com/story/payers-already-fretting-about-next-pharmapocalypse- pricey-pcsk9-cholestero/2014-05-07. Accessed April 12, 2016.
7. Navarese EP, Kołodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia:a systematic review and meta-analysis. Ann Intern Med. 2015;163(1):40-51.
8. Zhang XL, Zhu QQ, Zhu L, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123.
9. Liakos A, Athanasiadou E, Mainou M, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia [editorial]. Ann Intern Med. 2015;163(3):241.
10. Battaggia A, Donzelli A, Font M. Effects of proprotein convertase subtilisin/ kexin type 9 antibodies in adults with hypercholesterolemia [editorial]. Ann Intern Med. 2015;163(3):241-42.
11. Auer J, Berent R, Primus C. PCSK9 inhibitors and cardiovascular events [editorial]. N Engl J Med. 2015;373(8):773.
12. Goemann IM, Londero TM, Dora JM. PCSK9 inhibitors and cardiovascular events [editorial]. N Engl J Med. 2015;373(8):773-74.
13. Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol. 2015;65(24):2638-51.
14. Shrank WH, Barlow JF, Brennan TA. New therapies in the treatment of high cholesterol: an argument to return to goal-based lipid guidelines. JAMA. 2015;314(14):1443-44.
15. Pfizer. The evaluation of bococizumab (PF-04950615; RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-1). ClinicalTrials.gov Identifier NCT01975376. March 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT01975376?term=NCT01975376&ra nk=1. Accessed April 12, 2016.
16. Pfizer. The evaluation of bococizumab (PF-04950615; RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-2). ClinicalTrials.gov Identifier NCT01975389. March 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT01975389?term=NCT01975389&r ank=1. Accessed April 12, 2016.
17. Sanofi. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553(REGN727). ClinicalTrials.gov Identifier NCT01663402. April 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT01663402?term=NCT01663402&rank=1. Accessed April 12, 2016.
18. Amgen. Further cardiovascular outcomes research with PCSK9 Inhibition in subjects with elevated risk (FOURIER). ClinicalTrials.gov Identifier NCT01764633. January 2016. Available at: https://clinicaltrials. gov/ct2/show/NCT01764633?term=NCT01764633&rank=1. Accessed April 12, 2016.
19. Chambers JD, Chenoweth M, Cangelosi MJ, Pyo J, Cohen JT, Neumann PJ. Medicare is scrutinizing evidence more tightly for national coverage determinations. Health Aff (Millwood). 2015;34(2):253-60.
20. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489-99.
21. Robinson JG, Kastelein JJ. PCSK9 inhibitors and cardiovascular events [editorial]. N Engl J Med. 2015;373(8):774.
22. Center for Evidence-based Policy. Drug Effectiveness Review Project (DERP). Oregon Health & Science University. Available at: http://www.ohsu. edu/xd/research/centers-institutes/evidence-based-policy-center/evidence/ derp/index.cfm. Accessed April 12, 2016.
23. McDonagh MS, Jonas DE, Gartlehner G, et al. Methods for the Drug Effectiveness Review Project. BMC Med Res Methodol. 2012;12:140.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
25. Berkman N, Lohr K, Ansari M, et al. Grading the strength of a body of evidence when assessing health care interventions for the effective health care program of the Agency for Healthcare Research and Quality: an update. Methods Guide for Comparative Effectiveness Reviews. (Prepared by the RTI-UNC Evidence-based Practice Center under Contract No. 290-2007-10056-I). AHRQ Publication No. 13(14)-EHC130-EF. Rockville, MD: Agency for Healthcare Research and Quality. November 2013. Available at: https:// www.effectivehealthcare.ahrq.gov/ehc/products/457/1752/methods-guidance- grading-evidence-131118.pdf. Accessed April 12, 2016.
26. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809-19.
27. Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36(19):1186-94.
28. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007-17.
29. Hirayama A, Honarpour N, Yoshida M, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk-primary results from the phase 2 YUKAWA study. Circ J. 2014;78(5):1073-82.
30. Kereiakes DJ, Robinson JG, Cannon CP, et al. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy:The ODYSSEY COMBO I study. Am Heart J. 2015;169(6):906-15.
31. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand A-C, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344-53.
32. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol- lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126(20):2408-17.
33. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341-50.
34. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331-40.
35. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870-82.
36. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891-900.
37. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500-09.
38. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29-36.
39. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108-18.
40. Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-48.
41. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308(23):2497-506.
42. Koren MJ, Blom D, Giugliano RP, et al. Safety and tolerability of very low LDL-C levels in patients treated with 52 weeks of evolocumab (AMG 145). Circulation. 2014;130(Suppl 2):A16865. [Abstract 16865]
43. Desai NR, Giugliano RP, Zhou J, et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). J Am Coll Cardiol. 2014;63(5):430-33.
44. Tice JA, Ollendorf DA, Cunningham C, et al. PCSK9 inhibitors for treatment of high cholesterol: effectiveness, value, and value-based price benchmarks:draft report. A technology assessment. Institute for Clinical and Economic Review. September 8, 2015. Available at: http://icer-review.org/ wp-content/uploads/2015/04/PCSK9_Draft_Report_0908151.pdf. Accessed April 12, 2016.
45. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45.
46. Liberati A, Altman DG, Tetzlaff J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34.